The Salt Lake City company is paying a combined $87.5 million for Cyclica and Valence to expand its machine learning capabilities.
Samjin Pharmaceutical signed an agreement with Cyclica, a Canadian AI-based novel drug development platform company, for a joint research on AI novel drug development.
TORONTO & OXFORD, England--(BUSINESS WIRE)--Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (“Arctoris”), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimer’s disease. This planned expansion of the partnership follows the results from an initial engagement that yielded positive results for targets related to both oncology and neurodegenerative disease.
TORONTO--(BUSINESS WIRE)--Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs).
TORONTO--(BUSINESS WIRE)--Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery. Mike brings 24 years of drug discovery experience at GlaxoSmithKline (GSK), where he led drug discovery programs spanning multiple therapeutic areas with a highly successful track record. Most notably, Mike co-led the team who discovered umeclidinium, a regulatory-approved drug that is used in medicines for the treatment of various respiratory diseases. In his role at Cyclica, Mike will lead a growing team of drug discovery scientists who are advancing a sustainable pipeline of therapeutically rich and diverse assets.
TORONTO--(BUSINESS WIRE)--Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all.
TORONTO & SHANGHAI--(BUSINESS WIRE)--Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics with synthetic lethality approach, announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development.
CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc., (Nasdaq: VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug discovery, today announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.
OXFORD, England & TORONTO--(BUSINESS WIRE)--PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharma and biotechnology drug discovery programs over the next two years.